GRC Report Staff

The Norway Financial Supervisory Authority (Finanstilsynet) has published a warning about TIBIPRO, an entity identified with Spain as its issuer jurisdiction and referencing a Spanish CNMV warning notice. Compliance teams should treat TIBIPRO as a potentially unauthorized or high-risk counterparty and screen for any exposure. The source record is brief, so details of the underlying conduct should be confirmed in the linked CNMV notice.

The Norway Financial Supervisory Authority has published a warning about atlasgroupag.com, a website linked to Switzerland. The source link points to the Swiss regulator FINMA's warning list, which suggests the entity was first flagged there. Compliance teams should treat the domain as high risk and update screening and fraud controls accordingly.

A warning concerning Standards Reliance and its website, standardsreliance.com, has been published, and the source metadata is inconsistent: the record lists Norway's Financial Supervisory Authority as the regulator, but the linked notice and issuer field point to the Swiss Financial Market Supervisory Authority (FINMA). Compliance teams should treat the entity as a high-risk, potentially unauthorized provider and confirm the originating regulator before relying on the record in controls or reports.

The Hellenic Capital Market Commission (HCMC) has warned that Oversea Capital Markets Limited Single-Member Private Company (IKE) and the website overseatrades.com are not authorized to provide investment services or hold client funds. Compliance teams should treat both as unlicensed and high-risk, and update screening and monitoring controls accordingly.

The Norway Financial Supervisory Authority has listed a warning, originally issued by Luxembourg's CSSF, about fraudulent actors impersonating Eurizon Capital SGR S.p.A., Luxembourg Branch. Compliance teams should treat the name as a known impersonation vector and strengthen onboarding, payment, and client-communication controls accordingly.

Bank of America failed to report more than $5 billion in suspicious transactions in a timely manner and allowed serious deficiencies in its anti-money laundering controls to persist for years, even after regulators ordered the bank to correct them, according to enforcement actions announced Tuesday by the U.S. Treasury Department.

CVS Pharmacy and related corporate entities have agreed to pay $315 million to resolve federal allegations that the pharmacy chain filled unlawful prescriptions for opioids and other controlled substances for more than a decade, then sought reimbursement for many of those prescriptions from Medicare and other federal healthcare programs.